Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerging, the coronavirus disease 2019 (COVID-19) pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study in Biomedicine and Pharmacotherapy reviews the potential for curcumin, a natural […]

Read more

Anti-diabetic drug metformin inhibits disease progression in Alport syndrome mouse model

Researchers from Kumamoto University (Japan) have found that the anti-diabetic drug metformin significantly prolongs the survival of mice in a model that simulates the pathology of non-diabetic chronic kidney disease (ND-CKD) by ameliorating pathological conditions like reduced kidney function, glomerular damage, inflammation and fibrosis. Metformin's mechanism is different from existing therapeutics which only treat symptoms, such as the blood pressure […]

Read more

Two distinct types of COVID-19-associated acute respiratory distress syndrome identified

Approximately one in four patients hospitalized for the acute respiratory distress syndrome (ARDS) associated with severe COVID-19 infections may have a distinct phenotype (disease presentation) or biochemical profile associated with organ dysfunction, blood-clotting abnormalities and greater risk of death than patients with other, seemingly similar forms of the disease, researchers at Massachusetts General Hospital (MGH) have found. Among 263 patients […]

Read more

Researchers find cause of Guillain-Barre syndrome outbreak in Peru

In the spring of 2019, Peruvian neurologists saw a significant increase in the number of patients with Guillain-Barre syndrome (GBS). This rare disorder occurs when a person’s immune system damages the nerves, causing muscle weakness and sometimes paralysis. Although GBS typically only affects 3,000-6,000 people annually in the United States (or about 1 in 100,000), Peruvian doctors documented hundreds of […]

Read more

Long-COVID-19 is a significant risk in recovered patients post-hospitalization

The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen, has claimed the lives of over 2.79 million people worldwide. However, the long-term effects of the virus on human health and lifespan are less well known. A new study, which appeared in the British Medical Journal, reports on a retrospective study to […]

Read more

Rare genetic variant may explain severe COVID-19 in young healthy male patients

The novel coronavirus disease 2019 (COVID-19) pandemic has now been spreading for over a year, but several mysteries surrounding its diverse outcomes remain. How is it that some young healthy individuals contract the infection(caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and become critically unwell? Why do others, who are older and have underlying comorbidities, have less severe […]

Read more

Nanoparticles elicit neutralizing antibodies to diverse SARS-CoV-2 variants

Spike-protein-based nanoparticle vaccine candidates were retained longer in follicular dendritic cells and showed higher germinal center reactions in lymph node follicles compared to soluble spike protein vaccine. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected hundreds of millions worldwide since its emergence more than a year ago. The virus has also been mutating throughout the pandemic, with several […]

Read more

Antibody agents effective at neutralizing European, South African, and United States SARS-CoV-2 variants

Researchers in the United States have demonstrated the effectiveness of three antibody agents at neutralizing recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic. The team showed that one full-length antibody and two antibody domains each effectively neutralized pseudotyped virus containing key mutations found within the B.1.1.7 […]

Read more

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

With the onset of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it came to light that there were no specific and highly effective preventive or therapeutic agents against this virus. The result has been an enormous amount of studies reporting the efficacy or otherwise of novel drug candidates or repurposed drugs […]

Read more

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Researchers in Spain have conducted the most extensive study to date investigating the effectiveness of vaccinating healthcare workers with a single dose of the Pfizer-BioNTech vaccine to protect against coronavirus disease 2019 (COVID-19). The team says one dose of the vaccine induced a much stronger antibody response against the causative agent – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – […]

Read more
1 2 3 4